Add-on Acquisition • Life Science

Spark Therapeutics Acquires Genable Technologies

On March 7, 2016, Spark Therapeutics acquired life science company Genable Technologies for 15M USD

Acquisition Context

This is Spark Therapeutics’ 1st transaction in the Life Science sector.
This is Spark Therapeutics’ largest (disclosed) transaction.
This is Spark Therapeutics’ 1st transaction in Ireland.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	March 7, 2016
Target	Genable Technologies
Sector	Life Science
Buyer(s)	Spark Therapeutics
Deal Type	Add-on Acquisition
Deal Value	15M USD

Target Company

Genable Technologies

Dublin, Ireland

Genable Technologies Ltd. is a development stage gene therapy company.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Spark Therapeutics

Philadelphia, Pennsylvania, United States

Category	Company
Founded	2013
Sector	Life Science
Employees	50
Revenue	65M USD (2018)

DESCRIPTION

Spark Therapeutics, Inc. is a gene therapy provider seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark Therapeutics was founded in 2013 and is based in Philadelphia, Pennsylvania.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Ireland	1 of 1
Year: 2016	1 of 1
Size (of disclosed)	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Ireland M&A - 2016 M&A